Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays lowered their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Trading Down 0.8 %

NASDAQ CLLS opened at $1.56 on Monday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock’s 50-day simple moving average is $1.86 and its two-hundred day simple moving average is $2.04. Cellectis has a twelve month low of $1.53 and a twelve month high of $3.55. The company has a market capitalization of $86.71 million, a price-to-earnings ratio of -1.20 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period in the prior year, the business posted ($0.31) earnings per share. Research analysts forecast that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CLLS. XTX Topco Ltd bought a new stake in Cellectis in the 2nd quarter worth $29,000. First Affirmative Financial Network purchased a new position in Cellectis during the 3rd quarter valued at about $45,000. Principal Financial Group Inc. raised its position in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC lifted its holdings in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the period. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.